Mr. Paul Reid:

We would like to continue the discussions with the provider. It would be a commercially sensitive issue to share the price here and, as I said, we are bringing the decision back to the leadership group. We fully understand the finding in the UK last year. The UK, by making its decision, has left us in an isolated position. We want to do the right thing in terms of approval of this drug. We need to bring it back to the management team and also talk to the Department.